Increased complication rates of cardiac rhythm management devices in ESRD patients.

BACKGROUND Patients with end-stage renal disease (ESRD) have a high incidence of sudden cardiac death and may benefit from implantable cardioverter defibrillators (ICDs). However, ESRD also may predispose patients to device-related complications, potentially offsetting some of the benefits of prophylactic ICD placement. The purpose of this study is to compare the incidence of complications after cardiac rhythm management device (CRMD) implantation in patients with and without ESRD. METHODS An observational study was performed on 41 patients with ESRD and 123 controls without ESRD who had a CRMD (permanent pacemaker or ICD) implanted at a single institution from 1998 to 2005. Controls were matched for age, sex, type of device, and calendar year of device implantation. Primary and secondary end points were any complication and complications requiring intervention, respectively. RESULTS 23 complications occurred in 16 of 41 patients with ESRD (39%) versus 13 complications in 13 of 123 matched controls (11%; P < 0.001). Major complications occurred in 29% of patients with ESRD versus 5% of controls (P < 0.001), whereas minor complications occurred in 17% and 6%, respectively (P < 0.03). Hematoma, thrombosis, and device-related complications, including elevated defibrillation thresholds, were more common in patients with ESRD (P < 0.05 for all), and there also was a nonsignificant trend toward greater infection risk (P = 0.1). There were no fatal complications in either group. CONCLUSIONS Patients with ESRD had greater complication rates after CRMD implantation compared with matched controls, but these complications did not result in death. These results should be considered when evaluating patients with ESRD for prophylactic CRMD implantation, but do not support withholding such therapy.

[1]  Rod Passman,et al.  Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. , 2006, Heart rhythm.

[2]  D. Delurgio,et al.  Renal Insufficiency and the Risk of Infection from Pacemaker or Defibrillator Surgery , 2006, Pacing and clinical electrophysiology : PACE.

[3]  A. Collins,et al.  Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. , 2005, Kidney international.

[4]  H. Bonnemeier,et al.  Long term complications in single and dual chamber pacing are influenced by surgical experience and patient morbidity , 2005, Heart.

[5]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[6]  P. McCullough,et al.  Impact of Chronic Kidney Disease Upon Survival Among Implantable Cardioverter-Defibrillator Recipients , 2004, Journal of Interventional Cardiac Electrophysiology.

[7]  H. Schunkert,et al.  Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. , 2004, Chest.

[8]  J. Morrow,et al.  Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  G. Breithardt,et al.  Mortality, Morbidity, and Complications in 3,344 Patients with Implantable Cardioverter Defibrillators: , 2003 .

[10]  C. Herzog Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. , 2003, Kidney international. Supplement.

[11]  F. Manian Vascular and Cardiac Infections in End-Stage Renal Disease , 2003, The American journal of the medical sciences.

[12]  K. Eagle,et al.  Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. , 2003, Journal of the American Society of Nephrology : JASN.

[13]  R. Kerber,et al.  ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices , 2002 .

[14]  R. Kerber,et al.  ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). , 2002, Circulation.

[15]  L. Goldman,et al.  Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. , 2002, The New England journal of medicine.

[16]  J. Svendsen,et al.  Quality assessment of pacemaker implantations in Denmark. , 2002, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[18]  B. Wilkoff,et al.  The management of surgical complications of pacemaker and implantable cardioverter-defibrillators. , 2001, Current opinion in cardiology.

[19]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[20]  R. Shepard,et al.  Permanent Pacemaker Infections , 1999 .

[21]  N. Powe,et al.  Septicemia in dialysis patients: incidence, risk factors, and prognosis. , 1999, Kidney international.

[22]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[23]  F. Port,et al.  Morbidity and mortality in dialysis patients. , 1994, Kidney international.

[24]  W. Hörl,et al.  Uremia and infection: mechanisms of impaired cellular host defense. , 1993, Nephron.

[25]  D. Hayes,et al.  Venous complications after insertion of a transvenous pacemaker. , 1992, Mayo Clinic proceedings.

[26]  John A. Walker Myocardial calcification and cardiac dysfunction in chronic renal failure, by SG Rostand, C Sanders, KA Kirk, EA Rutsky, and RG Fraser. Am J Med 85:651–657, 1988 , 1989 .

[27]  R. G. Fraser,et al.  Myocardial calcification and cardiac dysfunction in chronic renal failure. , 1988, The American journal of medicine.